{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:00:42Z","timestamp":1769511642666,"version":"3.49.0"},"reference-count":24,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013650","name":"MorphoSys","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2021,11,15]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>B\u2010precursor cell acute lymphoblastic leukemia (B\u2010ALL) in adults is an aggressive and challenging condition, and patients with relapsed\/refractory (R\/R) disease after allogeneic stem cell transplantation (SCT), or noncandidates for SCT, have a particularly poor prognosis. The authors investigated the activity of the Fc\u2010modified anti\u2010CD19 antibody tafasitamab in adults with R\/R B\u2010ALL (NCT01685021).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with R\/R B\u2010ALL received single\u2010agent tafasitamab 12 mg\/kg weekly for up to four 28\u2010day cycles. Patients with complete remission (with or without neutrophil\/platelet recovery; complete remission [CR] or complete remission with incomplete count recovery [CRi]) after cycles 2, 3, or 4 could continue tafasitamab every 2 weeks for up to 3 further months. The primary end point was overall response rate (ORR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010two patients were treated (median, 2 prior lines of therapy; range, 1\u20108). Six patients completed 2 cycles, and 2 of these patients responded for an ORR of 9%; 16 patients (73%) progressed before their first response assessment. Responses lasted 8 and 4 weeks in the 2 patients with CR and minimal residual disease (MRD)\u2013negative CRi, respectively. Tafasitamab produced rapid B\u2010cell\/blast depletion in 21 of 22 patients within 1 to 2 weeks of first administration. Tafasitamab was well tolerated, with the most frequent adverse events being infusion\u2010related reactions (59.1%) and fatigue (40.9%). Grade 3 to 4 febrile neutropenia (22.7%) was the most common hematologic adverse event.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Tafasitamab monotherapy was associated with clinical activity in a subset of patients with R\/R B\u2010ALL, including short\u2010lasting CR and MRD\u2010negative CRi. Given its favorable tolerability profile, further development of tafasitamab in chemoimmunotherapy combinations and MRD settings should be explored.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.33796","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T13:33:49Z","timestamp":1627997629000},"page":"4190-4197","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase 2a, single\u2010arm, open\u2010label study of tafasitamab, a humanized, Fc\u2010modified, anti\u2010CD19 antibody, in patients with relapsed\/refractory B\u2010precursor cell acute lymphoblastic leukemia"],"prefix":"10.1002","volume":"127","author":[{"given":"Rebecca B.","family":"Klisovic","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology Emory School of Medicine Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing H.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine The University of Hong Kong Pokfulam Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Brugger","sequence":"additional","affiliation":[{"name":"MorphoSys AG Planegg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maren","family":"Dirnberger\u2010Hertweck","sequence":"additional","affiliation":[{"name":"MorphoSys AG Planegg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Winderlich","sequence":"additional","affiliation":[{"name":"MorphoSys AG Planegg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet V.","family":"Ambarkhane","sequence":"additional","affiliation":[{"name":"MorphoSys AG Planegg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00905-2"},{"key":"e_1_2_9_3_1","unstructured":"BESPONSA prescribing information.US Food & Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf. Accessed February 26 2021."},{"key":"e_1_2_9_4_1","unstructured":"KYMRIAH prescribing information.US Food & Drug Administration.https:\/\/www.fda.gov\/files\/vaccines%2Cblood%26biologics\/published\/Package\u2010Insert\u2010\u2010\u2010KYMRIAH.pdf. Accessed February 26 2021."},{"key":"e_1_2_9_5_1","unstructured":"BLINCYTO prescribing information.US Food & Drug Administration.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125557s017lbl.pdf. Accessed February 26 2021."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_280175"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1915"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32116"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.679.679"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31720"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112599"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0019-y"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2268"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-593269"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128388"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.373"},{"key":"e_1_2_9_22_1","unstructured":"US Food & Drug AdministrationFDA grants accelerated approval to tafasitamab\u2010cxix for diffuse large B\u2010cell lymphoma.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010tafasitamab\u2010cxix\u2010diffuse\u2010large\u2010b\u2010cell\u2010lymphoma. Accessed February 26 2021."},{"key":"e_1_2_9_23_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. v1.2020.National Comprehensive Cancer Network.https:\/\/www.nccn.org\/. Accessed February 26 2021."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.141"},{"key":"e_1_2_9_25_1","article-title":"Long\u2010term outcomes from the phase II L\u2010MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B\u2010cell lymphoma","volume":"293691","author":"Salles G","year":"2020","journal-title":"EHA Library"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.33796","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:20:31Z","timestamp":1760289631000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.33796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":24,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,11,15]]}},"alternative-id":["10.1002\/cncr.33796"],"URL":"https:\/\/doi.org\/10.1002\/cncr.33796","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"assertion":[{"value":"2021-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}